Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

AstraZeneca

1,704.00 SEK

+0.56 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.56 %
+9.20 %
+11.15 %
+22.33 %
+17.80 %
+16.59 %
+19.50 %
+86.68 %
+9,223.96 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.64T SEK
Turnover
296.64M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/20/2025, 7:00 AM

AstraZeneca: Koselugo (selumetinib) approved in the US

AstraZeneca
Regulatory press release7/14/2025, 6:00 AM

AstraZeneca: Baxdrostat met primary endpt in BaxHTN PhIII trial

AstraZeneca
Regulatory press release6/24/2025, 6:00 AM

AstraZeneca: Datroway approved in US for EGFRm lung cancer

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/28/2025, 1:06 PM

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

AstraZeneca
Regulatory press release2/6/2025, 7:00 AM

AstraZeneca: Final Results

AstraZeneca
Regulatory press release10/7/2024, 8:30 AM

AstraZeneca licenses lipid lowering Lp(a) asset

AstraZeneca
Regulatory press release3/7/2024, 11:00 AM

AstraZeneca: Notice of AGM

AstraZeneca
Regulatory press release2/21/2024, 7:00 AM

AstraZeneca: Filing of Form 20-F with SEC

AstraZeneca
Regulatory press release11/9/2023, 7:00 AM

AstraZeneca: 9M and Q3 2023 results

AstraZeneca
Press release7/25/2022, 6:11 AM

AstraZeneca: Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

AstraZeneca
Press release7/25/2022, 6:06 AM

AstraZeneca: Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

AstraZeneca
Press release7/25/2022, 6:01 AM

AstraZeneca: Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer

AstraZeneca
Regulatory press release7/19/2022, 6:01 AM

AstraZeneca: Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

AstraZeneca
Press release5/16/2022, 6:00 AM

AstraZeneca: PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

AstraZeneca
Regulatory press release12/14/2020, 9:00 AM

AstraZeneca to acquire Alexion Pharmaceuticals Inc

AstraZeneca
Regulatory press release12/3/2019, 9:00 AM

AstraZeneca divests Seroquel rights: US and Canada

AstraZeneca
Regulatory press release10/23/2018, 9:00 AM

AstraZeneca Extends Innate Pharma Collaboration

AstraZeneca
Regulatory press release10/1/2018, 9:00 AM

AstraZeneca PLC Announces Agreement with Cheplapharm for rights to Atacand in 28 European countries completed

AstraZeneca
Regulatory press release9/24/2018, 9:00 AM

Farxiga gets positive result in DECLARE-TIMI 58

AstraZeneca
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.